OncoZenge: Appoints LINK Medical as CRO for the phase III study - Redeye

Redeye comments on OncoZenge’s announcement of appointing LINK Medical as CRO for its pivotal phase III trial with BupiZenge. We view this as a natural and strategically sound step following the feasibility study conducted by LINK, ensuring both continuity and regional expertise as the company advances toward European market approval.

Länk till analysen i sin helhet: https://www.redeye.se/research/1127299/oncozenge-appoints-link-medical-as-cro-for-the-phase-iii-study?utm_source=finwire&utm_medium=RSS